Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:5/28/2008

PALO ALTO, Calif., May 28 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 31 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 151,800 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other cl
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015   ... und Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte ... Philips (NYSE: PHG, AEX: PHIA) gab heute ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird das ...
(Date:3/3/2015)... Experts and industry insiders from around the world ... REBELation exploring innovation, inspiration and world-changing ideas in Lexington, ... year, Alltech’s annual international conference traditionally draws more than ... join the REBELation at an extra discount registration closes ... which point the standard early registration rate will apply. ...
(Date:3/3/2015)... TORONTO , March 3, 2015 /CNW/- SQI Diagnostics ... and commercializes proprietary technologies and products for advanced ... Ryer CPA, CA, CFE  to its Management team. ... the Company in its transition from a development ... financing initiatives to advance the Company,s capital market ...
(Date:3/3/2015)... LITTLE FALLS, N.J. , March 3, 2015 /PRNewswire/ ... a biotechnology company specializing in the development of and ... of damaged tissues and organs, announced today that it ... Purchase Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin ... required under the Agreement, Amarantus made the final payments ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... software flexibility , Detect Released Oligosaccharides Using the ... Angela R. Downs Deborah A. Greer Stan ... , We compared the Eagle Eye ... SE2000 gel imager system,for imaging Fluorophore-Assisted ...
... cyclic-AMP detection kit and adenylate cyclase,(AC) toxin ... Inc. , Xinping Yang and Timothy G. Kingan, ... Kit is a highly sensitive and specific,antibody-based assay ... cAMP. The assay is based on the competition ...
... transduction efficiency and gene expression in,virtually any target cell line ... ,Stratagene , We describe three new ViraPort retroviral reporter vectors: ... , ,and pFB-Luc ... to determine transduction efficiency and gene expression in,virtually any target ...
Cached Biology Technology:Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 2Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 3Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 4Enzyme Immunoassay for Studying Intracellular Levels of cAMP 2Enzyme Immunoassay for Studying Intracellular Levels of cAMP 3Enzyme Immunoassay for Studying Intracellular Levels of cAMP 4Enzyme Immunoassay for Studying Intracellular Levels of cAMP 5Enzyme Immunoassay for Studying Intracellular Levels of cAMP 6Versatile Reporter Vectors for Monitoring Viral Transduction 2Versatile Reporter Vectors for Monitoring Viral Transduction 3Versatile Reporter Vectors for Monitoring Viral Transduction 4Versatile Reporter Vectors for Monitoring Viral Transduction 5Versatile Reporter Vectors for Monitoring Viral Transduction 6
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... - NOVEMBER 6, 2013: In an ... a New York-based physician-researcher from the Touro College of Osteopathic ... for levels of a growth protein that could help predict ... an analysis of findings in prior published studies, Touro researcher ...
... Mo. Researchers from the University of Missouri have ... cancer, the fourth leading cause of cancer death in ... deaths each year in the United States, and kills ... years, according to the National Cancer Institute. ...
... and largest of its kind study focusing on the ... in JAMA Pediatrics . The "Teen Longitudinal ... the National Institutes of Health (NIH) and is being ... Children,s Hospital. Thomas H. Inge, MD, PhD, with ...
Cached Biology News:Breastfeeding as a possible deterrent to autism -- a clinical perspective 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 3MU study finds more accurate method to diagnose pancreatic cancer 2Findings announced from landmark study on safety of adolescent bariatric surgery 2
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
Contact us for more information...
... Most sensitive silver stain. ... No stop baths or reversers ... lipids and polysaccharides. Linear ... to stain multiple gels per ...
... you to insert a transposable element of ... in vitro transposition. It uses TnsABC* Transposase ... DNA target. Target DNA may be a ... on your interests (6-8). If the insertion ...
Biology Products: